From: Benefits of an early cooling phase in continuous renal replacement therapy for ICU patients
Group A | Group B | P intergroup | |||||||
---|---|---|---|---|---|---|---|---|---|
Period 1 temperature 38°C | Period 1 temperature 36°C | ||||||||
n = 16 | n = 14 | ||||||||
H1 | H6 | H6-H1 | P Intra- group | H1 | H6 | H6-H1 | P Intra-group | H6-H1 | |
SAP mmHg | 118 [26] | 118 [26] | 0.2 [18.9] | 0.73 | 113 [26] | 125 [20] | 12.3[4.4] | 0. 01 | 0.06 |
DAP mmHg | 58 [13] | 60 [11] | 1.4 [9] | 0.65 | 58 [9] | 65 [10] | 6.3 [10.6] | 0.055 | 0.28 |
MAP mmHg | 77 [15] | 78 14] | 1.2 [11.4] | 0.67 | 71 [7] | 80 [12] | 8.9 [11] | 0.01 | 0.08 |
HR beat/min | 95 [16] | 92 [18] | −3 [5.9] | 0.06 | 103 [23] | 97 [28] | −5.5 [28.3] | 0.49 | 0.86 |
Lactates (mmol/L) | 4.1 [3.4] | 4.9 [4.5] | 0.4 [2.2] | 0.58 | 3.2 [2.3] | 2.6 [2.0] | 0.1 [0.3] | 0.31 | 0.2 |
Nep dosage μg/kg/min | 0.47 [1.19] | 0.47 [1.33] | 0.013 [0.2] | 0.72 | 0.93 [0.81] | 0.62 [0.56] | −0.55 [0.3] | 0.04 | 0.15 |
Increase of CA dose (no. patients) | 6 | 4 | |||||||
Decrease of CA dose (no. patients) | 6 | 7 | |||||||
Fluid infusion (no. patients) | 5 | 2 | |||||||
Total volume infused (ml) | 3500 | 2500 | |||||||
Therapeutic action (no. patients) | 8 | 5 |